Join to View Full Profile
1800 Orleans StreetBaltimore, MD 21287
Phone+1 410-955-5000
Fax+1 410-955-5001
Dr. Paul is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2021
University of ToledoResidency, Internal Medicine, 2013 - 2016
University of Calcutta School of MedicineClass of 2007
Certifications & Licensure
MD State Medical License 2017 - 2025
OH State Medical License 2013 - 2018
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- The real-world application of T-cell receptor constant beta-1 chain antibody assay in cutaneous T-cell lymphoma.Olivia Pierog, Taylor Craig, Jacky Jennings, Michael J Borowitz, Ananya Munjal
British Journal of Haematology. 2025-03-24 - Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma.Nadeem Tabbara, Marianna Zahurak, Cole H Sterling, Iris Margalit Trutzer, Jaroslaw Jedrych
Blood Advances. 2025-03-11 - Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape.Ashley L Cook, Surojit Sur, Laura Dobbyn, Evangeline Watson, Joshua D Cohen
Elife. 2025-02-17
Lectures
- Targeting MHC-linked wild type p53 with TCR mimic single chain diabody for cancer immunotherapy.2019 ASCO Annual Meeting - 6/1/2019
- Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Ludwig Johns Hopkins Researchers Devise New Strategy for Cancer ImmunotherapyMarch 2nd, 2021
Breakthrough in Controlling T Cell ActivationMay 13th, 2014
Investigators Develop Novel Treatment for T-cell Leukemias and LymphomasApril 3rd, 2024- Join now to see all
Grant Support
- TCR Targeting Antibodies for the Treatment of T cell CancersJOHNS HOPKINS UNIVERSITY2022–2027
- TCR Targeting Antibodies for the Treatment of T cell CancersJOHNS HOPKINS UNIVERSITY2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
